It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SRPT’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SRPT’s TA Score shows that 6 TA indicator(s) are bullish.
SRPT (@Biotechnology) experienced а +1.89% price change this week, while XBIO (@Biotechnology) price change was +16.39% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +30.64%, and the average quarterly price growth was +27.15%.
SRPT is expected to report earnings on Feb 27, 2024.
XBIO is expected to report earnings on Aug 11, 2023.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
|SRPT||XBIO||SRPT / XBIO|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XBIO's Valuation (14) in the Biotechnology industry is somewhat better than the same rating for SRPT (70). This means that XBIO’s stock grew somewhat faster than SRPT’s over the last 12 months.
XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that XBIO’s stock grew similarly to SRPT’s over the last 12 months.
XBIO's SMR Rating (96) in the Biotechnology industry is in the same range as SRPT (99). This means that XBIO’s stock grew similarly to SRPT’s over the last 12 months.
XBIO's Price Growth Rating (49) in the Biotechnology industry is in the same range as SRPT (63). This means that XBIO’s stock grew similarly to SRPT’s over the last 12 months.
XBIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that XBIO’s stock grew similarly to SRPT’s over the last 12 months.
2 days ago90%
2 days ago75%
2 days ago79%
2 days ago67%
2 days ago75%
2 days ago76%
2 days ago75%
6 days ago75%
2 days ago74%
2 days ago70%